Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Medical Oncology
What factors into your decision about whether to use HIPEC for advanced ovarian cancer?
Related Questions
How have you incorporated ctDNA into the clinical management of patients with gynecologic cancers?
When utilizing KN-A18 protocol, how do you best address symptoms of colitis/cystitis?
In a patient with stage IVB HER2 3+ high-grade serous endometrial cancer who had disease confined to a polyp and "microscopic" omental metastases, how long would you continue maintenance trastuzumab after chemotherapy?
Do you have concerns about the validity of the INTERLACE data, considering the long study recruitment period (10 years) and evolution of radiation techniques that have occurred during that time frame?
With the addition of pembrolizumab following chemoradiation per KEYNOTE-A18, would you be less likely to treat the paraaortic chain prophylactically?
What adjuvant treatment would you recommend for a patient with FIGO 2023 IIIB2 endometrioid endometrial adenocarcinoma (Grade 3, p53mut, MMR proficient), metastatic to the uterine serosa, bilateral ovaries, and anterior peritoneal reflection?
Would you use a GI regimen (FOLFOX) or a GYN regimen (Carboplatin/Paclitaxel +/- immuno) for a 71yo women with ascites, a large pelvic mass arising from the uterus (on CT), and peritoneal implants that are CDX2 positive, PAX 8 / WT-1 negative, p53 wild type, intestinal type?
Does being on maintenance pembrolizumab change how you manage patients with partial metabolic response on PET/CT 3 months after chemoradiation for cervical cancer?
What is your experience with in vitro chemosensitivity testing?
Would you add olaparib to maintenance immunotherapy for a patient with recurrent MMR-proficient, HER2-negative serous endometrial carcinoma?
